In a report released today, Sam Slutsky from LifeSci Capital maintained a Hold rating on Rain Therapeutics (RAIN – Research Report). The company’s shares opened today at $1.12.
According to TipRanks, Slutsky is a 3-star analyst with an average return of 3.5% and a 39.61% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Rain Therapeutics, Celldex, and Cogent Biosciences.
In addition to LifeSci Capital, Rain Therapeutics also received a Hold from Roth MKM’s Kumaraguru Raja in a report issued today. However, on May 22, Mizuho Securities maintained a Buy rating on Rain Therapeutics (NASDAQ: RAIN).
See Insiders’ Hot Stocks on TipRanks >>
Based on Rain Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $20.48 million. In comparison, last year the company had a GAAP net loss of $17.39 million
Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RAIN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rain Therapeutics Inc is a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which they are able to genetically select patients they believe will most likely benefit. Its lead product candidate, RAIN-32 is a small molecule, oral inhibitor of mouse double minute 2, which is oncogenic in numerous cancers.
Read More on RAIN:
- Rain Oncology Provides Company Update and Outlines Strategic Priorities of Milademetan Clinical Programs
- Rain Oncology Plummets after Lead Candidate Disappoints in Phase 3
- Rain Oncology Announces Topline Results from Phase 3 MANTRA Trial of Milademetan for the Treatment of Dedifferentiated Liposarcoma
- Rain Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Progress
